News

The popularity of phakic IOLs in both cataract and refractive surgery has soared in recent years with lens manufacturers all joining the race to develop better lenses with improved outcomes and fewer complications. Although phakic IOLs are considered the ideal tools for the correction of high ametropias, because of their excellent accuracy and predictability, stability of refraction from day one and independence of tissue healing, they have, unfortunately, been marred by reports of certain complications throughout their development history. These complications include corneal decompensation, chronic inflammation, iris atrophy (pupil distortion), cataract and glaucoma. Here, Ant?nio Marinho, MD, PhD discusses the influence of phakic IOLs on cataract and glaucoma development.

Globally, LASIK is a very popular refractive procedure, which provides excellent visual acuity and quality of vision in low to moderate myopia and hyperopia.1 In the mid-nineties, however, LASIK was performed even in extreme myopic errors (up to 23D) or in corneas that were too thin with or without Forme Fruste Keratoconus (FFKC).

The challenge of glaucoma surgery is not only to create a canal within the anterior chamber that acts as a pressure alleviator, it is to ensure that the canal is stable, will not close and, preferably, will alleviate intraocular pressure (IOP) to such an extent that medication is either no longer necessary or the frequency of dosing is minimized. This is the goal of every glaucoma surgeon and one that, unfortunately, is often not achieved, for a number of reasons.

Oertli survey

Ophthalmology is a branch of medicine that we, as ophthalmologists, regard as an elite branch of medicine and others, such as general surgeons and physicians, often consider as a minor and sometimes easy discipline. As a result of this misdirected preconception, a general practitioner, consultant or physician may not feel it necessary to fully inform us of a patient's health record because they do not consider that ophthalmic medications could, potentially, carry with them serious, sometimes life threatening side effects, if used inappropriately.

DSAEK will soon replace conventional PK surgery for the treatment of endothelial decompensation

Advanced surface ablation, such as LASEK and Epi-LASIK, defined as a refractive laser technique that does not create a lamellar flap, is the wave of the future, according to Richard Yee, MD. He said that advanced surface ablations are ideal procedures for problem cases, such as those with thin corneas and high myopia and is even better for routine cases.

QLT has formed a global co-development and licensing agreement with Retinagenix to develop active synthetic treatments for degenerative retinal diseases.

First described in 1881 by Litten 1 and attributed to Albert Terson, a French ophthalmologist who later described it in 1900, 2 Terson's syndrome is a condition defined as vitreous haemorrhage occurring in association with a subdural or subarachnoid haemorrhage (SAH). Here, Bastawrous and his team of colleagues describe a patient with Terson's syndrome and subsequent Candida endophthalmitis.

It has been demonstrated that a single compound is as effective as fixed combination therapy in lowering intraocular pressure (IOP), according to a study presented at the recent ARVO (Association for Research in Vision and Ophthalmology) meeting.

Many ophthalmic disorders give rise to neovascularization of the iris and neovascular glaucoma. Almost all of these disorders are characterized by retinal hypoxia and retinal capillary nonperfusion, the same factors involved in the development of retinal neovascularization. One of the most common causes is central retinal vein occlusion (CRVO), which is a visually disabling disease that is second in prevalence only to diabetic retinopathy.

When you attend an ophthalmology congress, what is it that you expect to gain? Does the opportunity to mingle with the elite inspire you to pay your congress fee, or do you want to learn new skills and improve your everyday practice? Certainly, people's motivations have been somewhat ambiguous in the past. With the style of the traditional meetings placing more emphasis on lecture-type presentations with no real discussion and less emphasis on the sharing of knowledge amongst participants, meeting attendees rarely had any input whatsoever.

In 1999, the World Health Organization (WHO) initiated its worldwide campaign, "Vision 2020 - The Right to Sight". The main aim of the programme was to eliminate the main causes of avoidable blindness by the target date of 2020. Hungary is participating in this "Fight for Sight" initiative. Here, J?nos N?meth summarizes the progress that he and his colleagues have made over the last five years, showing the current state of, and trends in, ophthalmic healthcare in Hungary, as well as the incidence of blindness in the country.

Didier Ducournau talks about the development and growth of the EVRS and on his personal vision for vitreoretinal surgeons.

Postoperative endophthalmitis is a rare but potentially devastating intraocular infection, which could lead to severe and permanent visual impairment or even the loss of an eye.1-3 With the average life expectancy on the increase, the prevalence of cataract in the older population and therefore the cataract surgical rate has increased in recent decades.1,3 Many have voiced their concerns that this rise in the number of surgical procedures could bring with it a rise in incidence of endophthalmitis, hence, evaluation of postoperative infection incidence is extremely important in every clinical setting.

CE marked in April of 2006, the KS-3Ai has become the first preloaded aspheric silicone IOL to be approved in Europe for use in cataract surgery. Although the product has yet to gain approval in the US market, it is already available in Japan and will shortly be entering clinics in Europe.

Alcon has added another device to its product portfolio in the form of the LADAR6000 excimer laser with high-speed ablation, which received FDA approval last month.

Swedish ophthalmologic research has a long tradition dating back to the slit lamp of Gullstrand of the early 20th century through later concepts such as the use of sodium hyaluronate in cataract surgery and latanoprost in glaucoma treatment. University departments of ophthalmology are present at the Karolinska Institute in Stockholm and at the universities of Uppsala, Lund (Lund and Malm?), Link?ping, Gothenburg and Ume?.

Dry eye ? the unknown menopausal symptom

No need for antimetabolites?

Combining benefits in glaucoma

Avastin does it again

Cataract surgery and AMD: there?s no link

DSEK: the pros and cons

OTE Readership Survey 2006

Intravitreal triamcinolone will, more often than not, lead to the development of cataracts in eyes with diabetic macular oedema (DME), according to the results of a study published in the March 17, 2006 issue of Eye.

Wound distortion by manipulation of two rigid cannulas during bimanual phaco through tight corneal incisions has been shown to be significant.

Until recently, treatment options for neovascular (wet) AMD have been limited. Thermal laser photocoagulation - a destructive mode of therapy - was indicated in a minority of neovascular cases, including extrafoveal and some cases of juxtafoveal choroidal neovascularization (CNV). Photodynamic therapy with verteporfin (PDT) marked a new era in the treatment of exudative AMD, since subfoveal lesions were no longer excluded from treatment. However, it remains that not all lesions are eligible for treatment and the beneficial effect of PDT has only been clearly evident in predominantly classic lesions.

CHMP gives Ganfort thumbs up

Age-related macular degeneration (AMD) is the worldwide leading cause of blindness. The severe form, choroidal neovascularisation (CNV), faces revolutionary times as new treatment modalities are introduced. Whereas one decade ago argon laser coagulation represented the standard treatment method, nowadays different treatments come into our clinical setting: classic CNV responds well to photodynamic therapy (PDT) with "off label" triamcinolone, and now occult CNV can be successfully treated with an array of treatment modalities: PDT, transpupillary thermotherapy (TTT), subretinal surgery, macular translocation, or anti-angiogenic therapy.